IDYA Annual Cash & Cash Equivalents
$157.02 M
+$88.39 M+128.78%
31 December 2023
Summary:
As of January 20, 2025, IDYA annual cash & cash equivalents is $157.02 million, with the most recent change of +$88.39 million (+128.78%) on December 31, 2023. During the last 3 years, it has risen by +$84.98 million (+117.97%). IDYA annual cash & cash equivalents is now at all-time high.IDYA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDYA Quarterly Cash And Cash Equivalents
$400.28 M
+$217.23 M+118.68%
30 September 2024
Summary:
As of January 20, 2025, IDYA quarterly cash and cash equivalents is $400.28 million, with the most recent change of +$217.23 million (+118.68%) on September 30, 2024. Over the past year, it has increased by +$243.26 million (+154.93%). IDYA quarterly cash and cash equivalents is now at all-time high.IDYA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDYA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +128.8% | +154.9% |
| 3 y3 years | +118.0% | +154.9% |
| 5 y5 years | +665.8% | +1028.8% |
IDYA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +128.8% | at high | +715.1% |
| 5 y | 5-year | at high | +360.9% | at high | +1075.0% |
| alltime | all time | at high | +2534.1% | at high | +1852.1% |
IDEAYA Biosciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $400.28 M(+118.7%) |
| June 2024 | - | $183.05 M(+69.0%) |
| Mar 2024 | - | $108.34 M(-31.0%) |
| Dec 2023 | $157.02 M(+128.8%) | $157.02 M(+3.4%) |
| Sept 2023 | - | $151.85 M(+47.7%) |
| June 2023 | - | $102.84 M(+53.0%) |
| Mar 2023 | - | $67.24 M(-2.0%) |
| Dec 2022 | $68.63 M(-25.4%) | $68.63 M(-32.7%) |
| Sept 2022 | - | $101.95 M(+107.6%) |
| June 2022 | - | $49.11 M(-11.2%) |
| Mar 2022 | - | $55.29 M(-39.9%) |
| Dec 2021 | $92.05 M | $92.05 M(-15.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $108.43 M(+19.9%) |
| June 2021 | - | $90.43 M(-33.9%) |
| Mar 2021 | - | $136.75 M(+89.8%) |
| Dec 2020 | $72.04 M(+111.5%) | $72.04 M(-11.3%) |
| Sept 2020 | - | $81.24 M(-44.9%) |
| June 2020 | - | $147.54 M(+316.1%) |
| Mar 2020 | - | $35.46 M(+4.1%) |
| Dec 2019 | $34.07 M(+66.1%) | $34.07 M(-12.3%) |
| Sept 2019 | - | $38.85 M(-55.9%) |
| June 2019 | - | $88.11 M(+149.6%) |
| Mar 2019 | - | $35.30 M(+72.2%) |
| Dec 2018 | $20.50 M(+244.0%) | $20.50 M |
| Dec 2017 | $5.96 M | - |
FAQ
- What is IDEAYA Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for IDEAYA Biosciences?
- What is IDEAYA Biosciences annual cash & cash equivalents year-on-year change?
- What is IDEAYA Biosciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for IDEAYA Biosciences?
- What is IDEAYA Biosciences quarterly cash and cash equivalents year-on-year change?
What is IDEAYA Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of IDYA is $157.02 M
What is the all time high annual cash & cash equivalents for IDEAYA Biosciences?
IDEAYA Biosciences all-time high annual cash & cash equivalents is $157.02 M
What is IDEAYA Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, IDYA annual cash & cash equivalents has changed by +$88.39 M (+128.78%)
What is IDEAYA Biosciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IDYA is $400.28 M
What is the all time high quarterly cash and cash equivalents for IDEAYA Biosciences?
IDEAYA Biosciences all-time high quarterly cash and cash equivalents is $400.28 M
What is IDEAYA Biosciences quarterly cash and cash equivalents year-on-year change?
Over the past year, IDYA quarterly cash and cash equivalents has changed by +$243.26 M (+154.93%)